50 results
8-K
EX-99.3
AGIO
Agios Pharmaceuticals Inc
9 Dec 19
Agios EstablishesProof-of-Concept for Mitapivat inNon-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
4:02pm
., University Medical Center Utrecht and an investigator in the study. “These new data demonstrate that chronic treatment with mitapivat is well tolerated … Study demonstrate that adults with PK deficiency are at increased risk of comorbidities and complications resulting from chronic hemolysis and iron
8-K
EX-99.3
AGIO
Agios Pharmaceuticals Inc
12 Jun 20
Entry into a Material Definitive Agreement
7:04am
the Phase 1 study of mitapivat demonstrate for the first time that PKR activation has the potential to address chronic hemolytic anemia and impact … of sickle cell disease, a chronic lifelong condition with few treatment options,” said Chris Bowden, M.D., chief medical officer at Agios. “Looking
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
4 Sep 19
Other Events
5:05pm
clinical trial in adults with PK deficiency, which is a rare disease characterized by chronic hemolysis and long-term serious complications. Data from … that presents as chronic hemolytic anemia, which is the accelerated destruction of red blood cells. The inherited mutations in PKR genes cause
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
1 Dec 20
Other Events
7:46am
to be the first disease-modifying therapy for people with pyruvate kinase deficiency, a chronic, lifelong hemolytic anemia that often leads to serious physical … regulatory authority.
About PK Deficiency
Pyruvate kinase (PK) deficiency is a rare, inherited disease that presents as chronic hemolytic anemia, which
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
15 Oct 14
Regulation FD Disclosure
12:00am
Ongoing Dose
Escalation
Initiated
October
Safety-dose limiting toxicity, dose modifications,
chronic toxicity
Pharmacokinetics-exposure, half … characterized by chronic hemolytic anemia
Poor prognosis
Presents in infancy or childhood with severe hemolytic anemia and jaundice
No disease-altering
8-K
EX-99.2
ir8a7m
11 Jun 21
Other Events
7:24am
8-K
EX-99.1
1hdn3lj7t806 oxwongj
13 Jan 14
Regulation FD Disclosure
12:00am
DEFA14A
rl263l67jx
12 Jan 21
Additional proxy soliciting materials
5:15pm
8-K
EX-99.1
8ysnob
29 Jul 21
Agios Reports Business Highlights and Second Quarter 2021 Financial Results
7:17am
8-K
EX-99.1
rp8jzjfywfd u05g
26 Jan 21
Other Events
4:14pm
8-K
EX-99.1
v0y9owy3n
16 Jun 14
Other Events
12:00am
8-K
EX-99.1
52th5m0l07 qaxl7jefu
8 Dec 14
Agios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies
12:00am
DEFA14A
EX-99.2
6q9d 4e3s8p
21 Dec 20
Additional proxy soliciting materials
7:10am
8-K
EX-99.2
om86od9etqojsv dpb
21 Dec 20
Regulation FD Disclosure
7:04am
8-K
EX-99.1
dnwpmsynhomrm6 6q
13 Jan 20
Regulation FD Disclosure
4:32pm
8-K
EX-99.1
ug0e3buzi73h
16 Oct 15
Regulation FD Disclosure
12:00am
8-K
EX-99.2
bfyz 3c0p9rnam
8 Jan 24
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
7:58am
424B5
hzk 3fchoo
8 Nov 19
Prospectus supplement for primary offering
5:03pm
424B5
gcsfoeis w2s
6 Nov 19
Prospectus supplement for primary offering
4:07pm